These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12085827)

  • 1. Update from the 8th CROI: adverse effects of HAART and structured treatment interruption.
    Bartlett JG
    Hopkins HIV Rep; 2001 May; 13(3):8-9. PubMed ID: 12085827
    [No Abstract]   [Full Text] [Related]  

  • 2. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
    Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
    AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults.
    Monier PL; Wilcox R
    Am J Med Sci; 2004 Jul; 328(1):48-56. PubMed ID: 15254441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy.
    Nicastri E; Dori L; Buonomini AR; Tommasi C; De Nardo P; Bellagamba R; Corpolongo A; Montano M; Sordillo P; Volpi A; Sarmati L; Andreoni M
    AIDS; 2012 Jul; 26(11):1451-2. PubMed ID: 22767346
    [No Abstract]   [Full Text] [Related]  

  • 6. Structured treatment interruptions in HIV/AIDS therapy.
    Lisziewicz J; Lori F
    Microbes Infect; 2002 Feb; 4(2):207-14. PubMed ID: 11880054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV news from Buenos Aires: Part 2--symmetries and semistops.
    Mascolini M
    IAPAC Mon; 2001 Oct; 7(10):294-308. PubMed ID: 11785462
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 10. When to start, when to STI (or, groping for the golden moment).
    Mascolini M
    IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605
    [No Abstract]   [Full Text] [Related]  

  • 11. Research sheds light on treatment interruption.
    Fauci A
    AIDS Alert; 2001 Sep; 16(9):114-6. PubMed ID: 11547494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special coverage: Retroviruses Conference 2006. Treatment interruption continues to be controversial strategy in HIV care. CROI studies show mixed results.
    AIDS Alert; 2006 Mar; 21(3):13-6. PubMed ID: 17378059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structured treatment interruption and immune reconstitution.
    Berger DS
    Posit Aware; 2002; 13(2):36-7. PubMed ID: 12004832
    [No Abstract]   [Full Text] [Related]  

  • 15. Preference for CD4-guided versus continuous HARRT in Thailand.
    Ananworanich J; Pumpradit W; Apateerapong W; Siangphoe U; Saenawat S; Phanuphak P; Hirschel B
    AIDS Care; 2008 Mar; 20(3):327-30. PubMed ID: 18351480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High thymic volume is associated with viral replication and immunologic impairment only early after HAART interruption in chronic HIV infection.
    Vallejo A; Valladares A; De Felipe B; Vivancos J; Gutierrez S; Soriano-Sarabia N; Ruiz-Mateos E; Lissen E; Leal M
    Viral Immunol; 2005; 18(4):740-6. PubMed ID: 16359240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 cell count-guided treatment interruption: be smart and wait for more evidence.
    Arduino R
    Clin Infect Dis; 2005 Mar; 40(5):735-7. PubMed ID: 15714421
    [No Abstract]   [Full Text] [Related]  

  • 19. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy].
    Zhao HX; Zhang FJ; Han N; Lan MD; Yao J; Liu ZY; Lu LH; Wei HS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Oct; 28(5):658-61. PubMed ID: 17121226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.